- Eramol is progressing with the construction of an 11,000 sq ft sterile manufacturing facility in Sevenoaks, Kent, expected to open in early 2026.
- The site will support small to medium batch production of sterile injectable products, targeting biotech, pharma, NHS, academia, and virtual pharma clients.
Eramol, a UK-based pharmaceutical contract development and manufacturing organisation (CDMO), has announced key milestones in the development of its new sterile manufacturing site in Sevenoaks, Kent. The facility is scheduled to open in early 2026.
Spanning 11,000 square feet, the facility will include a 1,900 square foot GMP Grade A/C cleanroom suite tailored for small to medium batch production of sterile injectable products. Additional features include modern office spaces and dedicated client reception areas to support end-to-end pharmaceutical services, including QP release, storage, and global distribution.
The site is purpose-built to comply with the 2023 EU GMP Annex 1 standards. It integrates advanced contamination control measures and environmental monitoring systems to ensure high levels of sterility assurance. Equipment to be installed includes a Fedegari autoclave and isolator technology for aseptic filling into 2ml and 10ml vials, with a focus on scalability from early- to late-phase or commercial production.
“The facility reflects our commitment to supporting clients with a flexible, compliant, and forward-thinking approach to sterile manufacturing,” said Peter Mollison, Co-CEO and Co-Founder at Eramol.
Installation of the isolator is expected in October 2025, with commissioning and qualification activities beginning in September. The company anticipates an MHRA inspection by the end of 2025, ahead of client onboarding.
Eramol’s new facility aims to serve a range of customers, including biotech firms, pharmaceutical companies, the NHS, academic institutions, and virtual pharma organisations seeking UK-based CDMO services.
